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Retarding progression of chronic renal disease: The neglected Following the original observation in type 1 diabetic
issue of residual proteinuria. nephropathy that reducing arterial blood pressure slowed
Background. Findings that early changes in proteinuria in- glomerular filtration rate (GFR) decline [1, 2], severaldependently predict long-term glomular filtration rate (GFR)
studies have definitely demonstrated that effective blooddecline (GFR) would highlight proteinuria as a major deter-
pressure control is renoprotective. Experimental andminant of progression in chronic renal disease.
Methods. We investigated whether percent changes (3 months clinical data have also highlighted proteinuria as an addi-
vs. baseline) in proteinuria (adjusted for concomitant changes tional and powerful predictor of progression and protein-
in GFR) and residual proteinuria at 3 months, predicted GFR uria reduction as an important strategy to retard or pre-[over a median (IQ range) follow up of 31.3 (24.5 to 50.3) months]
vent renal function loss [3, 4].in 273 patients with proteinuric chronic nephropathies enrolled
Studies in relatively small series of patients with dia-in the Ramipril Efficacy In Nephropathy (REIN) study.
Results. Short-term changes and residual proteinuria (r  betic [5] or nondiabetic [6] renal disease have indicated
0.23, P 0.0001 for both) significantly correlated with GFR convincingly that early reduction in proteinuria predicts
and, at multivariate analyses, independently predicted GFR less progression in the long-term. More recently, the Modi-(  0.23, P  0.0002;   0.21, P  0.0004, respectively).
fication of Diet in Renal Disease (MDRD) study foundFor comparable levels of residual proteinuria, patients with
in a remarkably larger number of patients that short-termgreater short-term reduction had slower GFR (0.28  0.04
mL/min/1.73 m2/ vs. 0.53  0.07 mL/min/1.73 m2/month, P  reduction in arterial blood pressure and proteinuria were
0.04). On ramipril and conventional treatment, specular short- both accompanied by a better preserved GFR through-
term changes in proteinuria (18.2  3.5% vs. 24.2  6.7%, out the whole study period [7]. However, between reduc-P  0.0001, respectively) were associated with significantly
tion in blood pressure and reduction in proteinuria, thedifferent GFRs. However, similar changes in proteinuria re-
sulted in a difference in GFR (ramipril, 0.39  0.07 mL/min/ actual determinant of improved long-term outcome was
1.73 m2/month; conventional therapy, 0.74  0.11 mL/min/1.73 left unresolved.
m2/month; P  0.01) that was sevenfold higher (0.35 vs. 0.05 Recently, the Ramipril Efficacy In Nephropathy (REIN)
mL/min/1.73m2/month) in patients with basal proteinuria 3
study [8] provided indirect evidence that in nondiabeticg/24 hours as compared to those with basal proteinuria 1 to 3
chronic nephropathy proteinuria predicted disease pro-g/24 hours (ramipril, 0.25  0.06 mL/min/1.73m2/month; con-
ventional therapy, 0.30 0.07 mL/min/1.73m2/month; PNS). gression and that proteinuria reduction obtained with an-
Conclusion. Regardless of blood pressure control and treat- giotensin-converting enzyme (ACE) inhibitor therapy was
ment randomization, short-term changes in proteinuria and renoprotective [9, 10]. Of note, the per-protocol strategy
residual proteinuria reliably predict long-term disease progres-
of targeting ACE inhibitors and non-ACE inhibitor ther-sion. Reducing proteinuria is renoprotective, particularly in
apy to blood pressure allowed comparable blood pressurenephrotic patients. As for arterial hypertension, proteinuria
should be a specific target for renoprotective treatment. control in ACE inhibitor and non-ACE inhibitor–treated
patients and prevented major changes in blood pressure
throughout the whole study period. This offered the
unique opportunity to assess the short- and long-term
renal effects of proteinuria reduction without the con-
founding effects of concomitant blood pressure changes.Key words: proteinuria reduction, residual proteinuria, chronic ne-
phropathies, progression, renoprotection. The broad aim of the present study was to clarify the
specific, independent contribution of proteinuria to theReceived for publication October 30, 2002
progression of chronic renal disease and of its reductionand in revised form January 17, 2002
Accepted for publication February 4, 2003 to the amelioration of the outcome. Specifically, we sought
to investigate whether in chronic nephropathy treat- 2003 by the International Society of Nephrology
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ment-induced changes in proteinuria may influence long- capsules of ramipril or placebo) were given in hospital
and patients monitored for 4 hours after ingestion. Theterm GFR decline (GFR) and whether residual pro-
teinuria (e.g., urinary protein excretion rate at 3 months study drug dose was increased every 2 weeks until “trough”
diastolic blood pressure (measured in the morning be-of treatment) also influenced GFR.
fore study drug administration) was reduced to under
90 mm Hg. Antihypertensive agents (but not ACE inhib-
METHODS
itors) were introduced (diuretics as first choice, centrally
The REIN trial [8–10] compared the rate of GFR de- acting sympatholytic agents and vasodilators, including
cline and the risk of progression to end-stage renal disease dihydropyridinic calcium channel blockers, as second and
(ESRD) in two groups of patients with proteinuric chronic third choice, respectively) were introduced, and their doses
nephropathies randomly allocated to the same degree adjusted to achieve and maintain diastolic blood pressure
of blood pressure control (diastolic blood pressure 90 under 90 mm Hg. In patients already receiving antihyper-
mm Hg) achieved with the ACE inhibitor ramipril or tensive agents, the study drug dose was increased and the
with placebo, plus non-ACE inhibitor antihypertensives dose of the other antihypertensive drugs progressively
as appropriate. reduced to avoid symptomatic hypotension. In each pa-
tient, the broad aim was to adjust the dose of the study
Patients
drugs to achieve and maintain the target blood pressure
Study participants were patients of either gender, be- with the minimum dose of concomitant antihypertensive
tween 18 and 70 years old, with proteinuric chronic ne- agents. ACE inhibitors or antagonists to angiotensin II
phropathy, with or without hypertension. Chronic ne- receptor could not be added to the study drugs during
phropathy was defined as creatinine clearance in the the study period. Each patient was examined by a physi-
range of 20 to 70 mL/min/1.73 m2 as a mean of three cian at baseline, every month during the first 3 months
monthly consecutive measurements, with a creatinine after randomization, and every 3 months thereafter. At
clearance variation of less than 30% in the 3 months each examination, arterial blood pressure was measured
prior to study entry (in order to exclude patients with with the patient in the sitting position in the morning
acute or rapidly progressive renal insufficiency). Persis- and before ingestion of the antihypertensive drugs, and
tent proteinuria was defined as a urinary protein excre- routine laboratory parameters, including 24-hour urinary
tion 1 g/24 hours over at least 3 months with no evi- protein excretion rate, were evaluated. At baseline, at 1,
dence of urinary tract infection or overt heart failure 3, and 6 months after randomization, and every 6 months
[New York Heart Assessment (NYHA) class III-IV]. thereafter, patients had their GFR centrally evaluated
Exclusion criteria were treatment with corticosteroids, at Mario Negri Institute for Pharmacological Research,
nonsteroidal anti-inflammatory drugs (NSAIDs), or im- Bergamo, by the plasma clearance of nonradioactive io-
munosuppressive drugs; acute myocardial infarction or hexol [11]. This is a precise and reliable indicator of the
cerebrovascular accident in the previous 6 months; se- GFR that tightly correlates (r  0.892, P  0.001) with
vere uncontrolled hypertension (diastolic blood pressure the renal clearance of inulin over a wide range of renal
115 mm Hg and/or systolic blood pressure220 mm Hg); function [11]. Urinary protein excretion was measured by
evidence or suspicion of renovascular disease, obstruc- the biuret precipitation method [12] in all participating
tive uropathy, insulin-dependent diabetes mellitus, colla- centers in order to minimize variation in protein mea-
gen disease, cancer, higher serum aminotransferase con- surement.
centrations, or chronic cough; drug or alcohol abuse;
Statistical analysispregnancy; breast feeding; and ineffective contraception.
According to the Declaration of Helsinki, all patients Baseline and follow-up mean arterial pressure (MAP),
provided signed written informed consent before study 24-hour urinary protein excretion rate, and GFR were
entry. evaluated in all patients randomized in the REIN study.
Individual GFR declines were estimated by linear regres-
Study design sion model (least squares method). To explore whether
According to baseline urinary protein excretion rate short-term changes in MAP and proteinuria and actual
(estimated by the mean of two consecutive measurements levels of achieved MAP and proteinuria predicted dis-
2 weeks apart), before randomization and within each ease progression in the long-term, we evaluated whether
clinical center, patients were separated into two strata and to which extent GFR during the whole follow-up
(stratum 1, 1.0 to 2.9 g/24 hours; stratum 2,3 g/24 hours) period was correlated with short-term percent changes (3
and were then randomly assigned 1.25 mg capsules of months vs. baseline) in MAP or 24-hour urinary protein
ramipril or of placebo (identical appearance) on a 1:1 excretion rate and with effectively achieved MAP and
basis within each stratum. The first dose of the study proteinuria (residual proteinuria) at 3 months and through-
out the following study period (follow-up proteinuria).drugs, and that of increment dosages (i.e., 2.5 or 5.0 mg
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Table 1. Main basal clinical characteristics of the study patients as a whole (overall) and according to randomization to ramipril or conventional
treatment and to basal proteinuria 1 to 3 g/24 hours (stratum 1) or 3 g/24 hours (stratum 2)
Overall Ramipril Conventional Stratum 1 Stratum 2
Age years 48.70.8 47.31.1 50.21.2 49.31.1 47.91.3
Gender M/F 204/69 108/31 96/38 121/43 83/26
Disease glomerular/other 143/130 80/59 63/71 73/91 70/39a
Mean arterial pressure mm Hg 107.90.7 107.11.03 108.61.05 107.21.0 108.91.0
Glomerular filtration rate mL/min/1.73 m2 44.51.1 46.61.7 42.31.5 47.61.4 39.81.7
Proteinuria g/24 hours 3.20.2 3.30.2 3.10.2 1.70.1 5.40.3b
Glomerular filtration rate–corrected proteinuria
g/24 hours/mL/min/1.73 m2 0.090.01 0.090.01 0.090.01 0.040.00 0.160.01b
a P  0.01, b P  0.0001 vs. stratum 1
Table 2. Main clinical characteristics at 3 months after randomization of the study patients as a whole (overall) and according to randomization
to ramipril or conventional treatment and to basal proteinuria 1 to 3 g/24 hours (stratum 1) or 3 g/24 hours (stratum 2)
Overall Ramipril Conventional Stratum 1 Stratum 2
Mean arterial pressure mm Hg 103.30.7 100.70.9 105.90.9a 101.80.9 105.51.0b
Glomerular filtration rate mL/min/1.73 m2 42.51.1 44.61.7 40.21.6 46.31.4 36.71.8c
Proteinuria g/24 hours 3.00.2 2.50.2 3.40.3d 1.70.1 4.80.3c
Glomerular filtration rate–corrected proteinuria
g/24 hours/mL/min/1.73 m2 0.090.01 0.080.01 0.110.01d 0.040.00 0.170.01a
aP  0.0001 vs. ramipril; bP  0.001; cP  0.0001 vs. stratum 1; dP  0.001
On the same line, the predictive value of the above taken as the primary efficacy variables of the study,
served to predict the long-term beneficial effects of reno-covariates was evaluated by univariate and multivariate
analyses where GFR was considered as the outcome protective treatments as well as to early detect the func-
tional changes associated with disease progression.variable. To account for the confounding effect of acute,
hemodynamic changes in GFR associated with blood Thus, the present study was primarily aimed to evaluate
the relationships of short-term changes in GFR-correctedpressure reduction and/or ACE inhibition therapy, be-
fore analyses both 3-month (residual) and baseline pro- proteinuria and residual proteinuria with long-termGFR.
teinuria values were corrected for 3-month and baseline Secondary aims were to evaluate also the relationships
GFR values, respectively [GFR-corrected proteinuria between basal (prerandomization), or follow-up (6-month
proteinuria (g/24 hours)/GFR (mL/min/1.73 m2)]. Actu- postrandomization to study end) GFR-corrected protein-
ally, both blood pressure reduction and ACE inhibitor uria and GFR. Correlation analyses were carried out
therapy have been reported to acutely decrease the GFR by using Pearson’s r coefficient for continuous variables
[13]. This may contribute to reduce protein ultrafiltration [15]. Multivariate analyses were performed by means of
regardless of the effects on the intrinsic size-selective prop- multiple regression. Standardized  coefficients were pro-
erties of the glomerular barrier. Thus, correcting treat- vided. Sensitivity and specificity of short-term changes in
ment-induced changes in proteinuria for the concomitant proteinuria and of residual proteinuria (outcome, or	
changes in GFR may help evaluating the specific effects median value of GFR) were evaluated by receiver op-
of treatment on the size selectivity properties of the glo- erator characteristic (ROC) curves [16] using Analyze-
merular barrier, without the confounding effects of the it for Microsoft Excel (Trial version 1.62, Analyze-it Soft-
hemodynamic changes associated with blood pressure ware, Ltd., Leeds, UK, 1997–2000). The area under the
reduction and/or ACE inhibition [14]. On the other hand, curve (AUC) was provided with the 95% CI. Values
the natural history of most proteinuric nephropathies is were mean  SEM, unless otherwise stated.
characterized by a progressive increase in proteinuria
paralleled by a progressive decrease in GFR [9, 10], both
RESULTStrends contributing to increase GFR-corrected protein-
A total of 273 patients followed for a median (inter-uria. Thus, an increase in GFR-corrected proteinuria can
quartile range) of 31.3 (24.5 to 50.3) months were avail-be taken as a sensitive and early indicator of disease
able for outcome analyses. Their main characteristics atprogression.
baseline, at 3 months after randomization, and on follow-Due to the above, short-term changes in GFR-corrected
up (from 6 months to study end) are given in Tables 1,proteinuria and the actual levels of GFR-corrected pro-
teinuria achieved at 3 months (residual proteinuria), 2, and 3, respectively. During the first 3 months after
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Table 3. Main clinical characteristics on follow-up (data averaged from 6 months to study end) of the study patients
as a whole (overall) and according to randomization to ramipril or conventional treatment and to
basal proteinuria 1 to 3 g/24 hours (stratum 1) or 3 g/24 hours (stratum 2)
Overall Ramipril Conventional Stratum 1 Stratum 2
Mean arterial pressure mm Hg 103.10.5 101.00.7 105.10.8a 102.10.7 104.80.8b
GFR mL/min/1.73 m2 38.41.2 41.31.7 35.21.5c 43.21.5 30.91.7d
Proteinuria g/24 hours 2.90.1 2.50.2 3.20.2a 1.90.1 4.60.3d
GFR-corrected proteinuria g/24 hours/mL/min/1.73 m2 0.100.01 0.090.01 0.120.01a 0.060.00 0.190.02d
aP  0.001 vs. ramipril; bP  0.05; cP  0.01; dP  0.0001 vs. stratum 1
Table 4. Univariate correlations between mean arterial pressure (MAP) or proteinuria (absolute values at basal and 3 months, percent
changes at 3 months vs. basal, average values on follow-up) and changes in glomerular filtration rate (GFR)
Basal 3 months (residual) % changes (vs. basal) Follow-up
r P r P r P r P
MAP 0.13 0.04 0.20 0.001 0.08 0.18 0.21 0.001
Proteinuriaa 0.14 0.02 0.23 0.0001 0.23 0.0001 0.27 0.0001
aCorrected by GFR
randomization, 24-hour proteinuria significantly de- 0.04). On the same line, at multivariate analyses, GFR
was significantly predicted by 3-month percent changescreased from 3.25  0.24 g/24 hours to 2.53  0.22 g/24
hours (P  0.0001) in the ramipril group and increased in proteinuria and by actual levels of MAP and protein-
uria achieved at 3 months and on follow-up, but not byfrom 3.08  0.18 g/24 hours to 3.39  0.27 g/24 hours
(P  0.09) in the placebo group. At 3 months, the GFR 3-month percent changes in MAP (Table 5).
Of note, the correlation between 3-month (residual)decreased from 46.6  1.7 mL/min/1.73 m2 to 44.6  1.7
mL/min/1.73 m2 (P  0.002) in the ramipril group and proteinuria and GFR was even more significant than
the correlation between follow-up proteinuria and GFRfrom 42.3  1.5 mL/min/1.73 m2 to 40.2  1.6 mL/min/
1.73 m2 (P  0.0004) in the placebo group. Thus, GFR- (Table 4). On the same line, at multivariate analysis, 3-
month proteinuria was even more predictive of GFRcorrected proteinuria significantly decreased from 0.091
0.009 to 0.076 0.009 (P 0.0005) in the ramipril group than follow-up proteinuria (Table 5).
In the whole study group (Fig. 1), and in the two strataand significantly increased from 0.090  0.007 to 0.110 
0.010 (P  0.001) in the placebo group. These opposite (Fig. 2), ramipril-treated patients had a short-term reduc-
tion in proteinuria that was associated with a slowertrends were significantly different (P  0.0001).
Regardless of the treatment group, GFR during the GFR and, vice versa, conventionally treated patients
had a short-term increase in proteinuria that was associ-whole follow-up period significantly correlated with
short-term (3-month) percent changes in proteinuria and ated with a faster GFR (Table 6). Of note, percent
short-term changes in proteinuria in the whole studywith actual levels of MAP and proteinuria achieved at
3 months (residual proteinuria) and on follow-up (fol- group and in the two strata were very well comparable
either among ramipril-treated and conventionally treatedlow-up proteinuria), but not with 3-month percent
changes in MAP (Table 4). Thus, the rate of GFR decline patients (Table 6). On the other hand, however, the impact
on follow-up GFR of comparable short-term changesprogressively increased for increasing tertiles of 3-month
proteinuria. However, within each tertile, patients who in proteinuria was quite different in the whole study
group and in the two strata (Figs. 1 and 2). In the wholehad a 3-month reduction in proteinuria tended to have
a slower GFR decline than patients with no 3-month study group, the opposite changes in proteinuria (Table
6) resulted in a difference in GFR between ramipril-reduction in proteinuria (lowest tertile, 0.13  0.05 mL/
min/1.73 m2/month vs. 0.19  0.07 mL/min/1.73 m2/ treated and conventionally treated patients of about 0.1
mL/min/1.73 m2 per month (Table 6). However, in stra-month; middle tertile, 0.33 0.04 mL/min/1.73 m2/month
vs. 0.41  013 mL/min/1.73 m2/month; highest tertile, tum 1 and stratum 2 patients, changes in proteinuria
resulted in a difference in GFR between ramipril-0.55  0.12 mL/min/1.73 m2/month vs. 0.73  0.11 mL/
min/1.73 m2/month). As a consequence, regardless of the treated and conventionally treated patients of about 0.05
mL/min/1.73 m2 per month and 0.35 mL/min/1.73 m2 pertertile, GFR was significantly slower in patients with
short-term reduction than in those without short-term month (Fig. 2, Table 6), respectively. Thus, comparable
short-term (3-month) changes in proteinuria in the tworeduction in proteinuria (0.28  0.04 mL/min/1.73 m2/
month vs. 0.53  0.07 mL/min/1.73 m2/month, P  strata resulted in a difference inGFR between ramipril-
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Table 5. Multivariate analysis of the relationships between mean arterial pressure (MAP) or 24-hour proteinuria (absolute values at basal
and 3 months, percent changes at 3 months vs. basal, average values on follow-up) and changes in glomerular filtration rate (GFR)
Basal 3 months (residual) % changes (vs. basal) Follow-up
 P  P  P  P
MAP 0.12 0.06 0.17 0.004 0.05 0.43 0.18 0.004
Proteinuriaa 0.13 0.03 0.21 0.0004 0.23 0.0002 0.24 0.0001
a Corrected by GFR
above the median (P  0.05) and about threefold faster
in those with residual proteinuria above the median as
compared to those with residual proteinuria below the
median (P  0.0001, Table 7). As expected, the fastest
GFR was observed in patients with short-term reduc-
tions below the median combined to residual proteinuria
above the median, and the slowest one in those with
short-term reductions above the median combined to
residual proteinuria below the median (Table 7), differ-
ences in GFR between these subgroups being highly
significant (P  0.0001). Intermediate GFRs were ob-
served in the remaining two subgroups of patients with
both short-term reduction and residual proteinuria
above or below the median, respectively (Table 7).Fig. 1. Correlation between mean 3-month changes in 24-hour protein-
uria and mean change in glomerular filtration rate (GFR) on follow- Sensitivity and specificity analyses found that the ROC
up in the study group as a whole and in the two subgroups of patients curves of short-term changes in proteinuria and of resid-
randomized to ramipril or conventional treatment.
ual proteinuria were both significantly different from no
discrimination (P  0.0001 and P  0.01, respectively)
in predicting GFR above or below the median value.
However, the performance of residual proteinuria in pre-treated and conventionally treated patients that was
dicting GFR (Fig. 3) was superior to that of short-termabout sevenfold higher among patients with nephrotic-
changes in proteinuria [AUC (95% CI): 0.63 (0.57 torange proteinuria (stratum 2) as compared to those with
0.70) and 0.58 (0.51 to 0.65), respectively].nonnephrotic proteinuria (stratum 1) (Fig. 2, Table 6).
Different outcomes in the different considered sub-
groups were not explained by differences in dietary so-
DISCUSSIONdium or protein intake since 24-hour urinary sodium and
The present study found that in proteinuric, chronicurea excretion in the two strata (stratum 1: urinary Na

nephropathies long-term GFR decline is predicted byexcretion 170  5 mEq/24 hours, urinary urea excretion
short-term (3-month) changes in GFR-corrected urinary19.5  0.6 g/24 hours; stratum 2: urinary Na
 excretion
protein excretion rate and by blood pressure control and177  11 mEq/24 hours, urinary urea excretion 18.4 
residual proteinuria at 3 months. Regardless of treat-0.8 g/24 hours) and in the two treatment groups (ramipril:
ment, short-term changes in proteinuria were negativelyurinary Na
 excretion 175  6 mEq/24 hours, urinary
correlated with GFR, short-term reductions predictingurea excretion 19.6  0.7 g/24 hours; conventional: uri-
slower GFRs and short-term increases faster GFRsnary Na
 excretion 171  9 mEq/24 hours, urinary urea
in the long run. On the contrary, 3-month blood pressureexcretion 18.4  0.7 g/24 hours) were comparable. As
and proteinuria were positively correlated with GFR,expected, however, a higher proportion of patients were
specifically, lower blood pressure or less proteinuria as-taking concomitant antihypertensive medications (includ-
sociated with less progression and higher blood pressureing diuretics, beta blockers, or calcium channel blockers)
or more proteinuria with more progression. In harmonyin stratum 2 as compared to stratum 1, and in the conven-
with correlation analyses, multivariate analyses foundtional as compared to the ramipril treatment group (data
that short-term changes in proteinuria and the actual levelsnot shown).
of blood pressure and proteinuria achieved at 3 monthsRegardless of stratification and treatment randomiza-
independently predicted GFR decline in the long-term.tion, GFR was about 50% faster in patients with short-
On the contrary, short-term changes in blood pressureterm reductions in GFR-corrected proteinuria below the
median as compared to those with short-term reductions failed to predict subsequent GFR decline. Of note, the
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Fig. 2. Correlation between mean 3-month
changes in 24-hour proteinuria and mean
change in glomerular filtration rate (GFR)
on follow-up in patients with basal proteinuria
1 to 3 g/24 hours (stratum 1) (A ) or 3 g/24
hours (stratum 2) (B ) as a whole and ac-
cording to randomization to ramipril or con-
ventional treatment.
Table 6. Percent changes (vs. basal) in 3-month 24-hour proteinuria, changes in glomerular filtration rate (GFR), and correlations between




Proteinuria changes at 3 months %a 2.63.9 18.23.5 24.26.7b
GFR mL/min/1.73 m2/month 0.400.04 0.310.05 0.490.06c
Correlation r 0.23 0.33 0.15
P 0.0001 0.0001 0.09
Stratum 1
Proteinuria changes at 3 months %a 2.95.7 17.34.5 25.110.3b
GFR mL/min/1.73 m2/month 0.280.04 0.250.06 0.300.07
Correlation r 0.19 0.41 0.10
P 0.01 0.0001 0.37
Stratum 2
Proteinuria changes at 3 months %a 2.35.0 19.55.9 22.97.1b
GFR mL/min/1.73 m2/month 0.570.07 0.390.07 0.740.11d
Correlation r 0.34 0.22 0.30
P 0.0003 0.12 0.03
aCorrected by GFR; bP  0.0001 vs. ramipril; cP  0.05 vs. ramipril; dP  0.01 vs. ramipril
Table 7. Changes in glomerular filtration rate (GFR) in different subgroups according to short-term (3-month) changes in GFR-corrected
proteinuria (above or below the median) and residual (3-month) GFR-corrected proteinuria (above or below the median)
3-month GFR-corrected proteinuria g/24 hours/mL/min/1.73 m2
Changes in GFR-corrected
proteinuria % 0.05a mL/min/1.73 m2/month 	0.05a mL/min/1.73 m2/month Overall mL/min/1.73 m2/month
3.25a 0.190.04 0.460.07b 0.280.04
Number 90 47 137
	3.25a 0.200.06 0.670.09c 0.510.07d
Number 47 89 136
Overall 0.190.03 0.600.07e 0.400.04
Number 137 136 273
a Median value; bP  0.01; cP  0.01; dP  0.05 vs. 3.25; eP  0.0001 vs.  0.05
slowest disease progression was achieved when short-term netic role in renal disease progression. Evidence pre-
sented herein that both short-term changes in proteinuriaproteinuria reduction was combined with lowest residual
proteinuria. This finding was consistent with a major con- and residual proteinuria preceded and reliably predicted
long-term GFR decline is a possible further argument.tribution of proteinuria to disease progression. Proteins
filtered through the glomerular capillary may have an Availability of individual GFRs, computed through
repeated GFR measurements performed by a standard-intrinsic renal toxicity, which would possibly contribute
to the progression of the lesions (for review see refer- ized and centralized method (e.g., iohexol plasma clear-
ance [11]), allowed us also to explore the impact of com-ences [3, 17]). Previous findings that excess of urinary
proteins correlated with faster GFR decline [4] could parable short-term changes in proteinuria on follow-up
GFR decline in patients with different levels of basalpossibly suggest that enhanced protein traffic through
the glomerular barrier may play at least some pathoge- proteinuria. Thus, in patients with a 24-hour proteinuria
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more short-term proteinuria reduction combined to less
residual proteinuria, whereas the fastest progression by
opposite changes (e.g., less short-term reduction com-
bined to more residual proteinuria, respectively). Of note,
the predictive performance of residual proteinuria was
superior to that of short-term changes in proteinuria and,
on average, the relative importance of residual protein-
uria in predicting long-term GFR decline exceeded that
of short-term reduction by about two times. Finding that,
regardless of the severity of proteinuria at study entry,
residual proteinuria was the strongest predictor of out-
come may serve to further emphasize the importance of
treatment titration to residual proteinuria in order to
maximize renoprotection. Information on residual pro-
teinuria can be usefully integrated by data on short-term
changes in proteinuria. In particular, short-term changes
in proteinuria may reflect the individual responsivenessFig. 3. Sensitivity and specificity of (3-month) residual proteinuria to
predict the levels above or below the median value of long-term changes to renoprotective therapy, mild or no reductions early
in glomerular filtration rate (GFR), assessed by receiving operator identifying less responsive patients for whom intensifiedcharacteristic (ROC) curve analysis (dark line) or by no discrimination
or additional treatments may be indicated.(light line). The ROC curve shows the true positive rate (sensitivity)
as the proportion of cases above the median that were classified at In the present study the gradual, response-driven up-
lower values and the true negative rate (specificity) as the proportion
titration of the study drugs prevented a sudden bloodof those below the median who were classified at higher values, at a
cutoff level of 0.5. These numbers were plotted against each other for pressure reduction that would theoretically predict less
each possible cutoff value to produce the ROC curve. The area under kidney hypoperfusion and better preserved glomerular
the curve (AUC) indicates the performance of residual proteinuria as
pressure. This most likely explained why the GFR did nota predictor of long-term GFR.
acutely decrease with ACE inhibitor therapy. Actually,
during the first 3 months of the study, in both ACE inhib-
itor– and non-ACE inhibitor–treated patients, short-term
of less than 3 g, who, as a whole, had a relatively slow GFR changes closely paralleled the changes observed
GFR decline, short-term increases or decreases in pro- during the remaining follow-up period. This may explain
teinuria resulted only in small differences in follow-up why correction for concomitant changes in GFR so re-
GFRs. On the contrary, in patients with proteinuria of 3 g markably increased the predictive value of short-term
or more, comparable short-term changes in proteinuria changes in proteinuria.
predicted quite more consistent differences in follow-up
GFR decline. In other words, the impact of short-term
CONCLUSIONchanges in proteinuria on long-term outcome was more
apparent for increasing levels of baseline proteinuria, We found that in proteinuric chronic nephropathies,
regardless of blood pressure control and treatment ran-being negligible in patients with mild proteinuria and
extremely relevant in those with heavy urinary protein domization, short-term changes in proteinuria and the
actual levels of residual proteinuria reliably predictedexcretion rate. These findings may explain why ACE
inhibitors, which exert at least part of their renoprotec- long-term disease progression, their predictivity being
maximized when they were considered in combinationtive effect by limiting protein traffic and proteinuria [18],
were only marginally effective in studies that involved and after correction for the concomitant GFR values. The
long-term favorable impact of short-term reduction inpredominantly patients with subclinical or no proteinuria
[19, 20], but were on the contrary remarkably renopro- proteinuria was particularly strong in patients with higher
levels of baseline urinary protein excretion rate. Thesetective in others that electively included patients with
heavy, nephrotic range proteinuria [9, 21]. This also ex- findings would imply that any treatment targeted at effec-
tively reducing urinary protein excretion rate will possi-plains why a meta-analysis of 1860 patients enrolled in
11 randomized trials found that the beneficial effect of bly have a long-term beneficial effect on disease progres-
sion, particularly in patients with heavy proteinuria.ACE inhibitors on renal disease progression (defined as
doubling of basal serum creatinine concentration or on- Thus, as for arterial hypertension, proteinuria should be
a specific target for renoprotective treatment, the goalset of ESRD) was greater in patients with higher baseline
proteinuria [22]. of treatment being reducing urinary proteins to 0.5 g/day
or less [23].Of note, the slowest GFR decline was predicted by
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